Across all the tumor types, metastatic samples were approximately 2.5 times more likely to be B2M negative compared to primary tumor samples (Odds ratio ~ 0.39 [CI 0.18 - 0.81], p-value ~ 0.012). This evidence concerns the gene B2M and neoplasm.